ICONIC: Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer

Sponsor

Royal Marsden NHS Foundation Trust (Other)

Overall Status

Recruiting

CT.gov ID

NCT03399071

Collaborator

Merck KGaA, Darmstadt, Germany (Industry)

Enrollment

Location

Arm

96.5

Anticipated Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

A single centre phase II trial of peri-operative chemo-immunotherapy in operable gastro-oesophageal adenocarcinoma (GOA). This trial is designed to evaluate the safety and efficacy of administering Avelumab, an anti-PD-L1 monoclonal antibody, with cytotoxic FLOT chemotherapy for patients with operable GOA treated according to a peri-operative protocol.

This trial is in 2 stages: the first stage will establish the safe and tolerated maximum administered dose (MAD) of Avelumab in combination with FLOT and the second stage will assess the efficacy of this combination therapy in achieving pathological complete response (pCR) and peri-operative safety.

Condition or Disease	Intervention/Treatment	Phase
Gastric Adenocarcinoma Oesophageal Adenocarcinoma	Drug: FLOT-A	Phase 2

Detailed Description

Patients will receive chemo-immunotherapy consisting of FLOT chemotherapy (Folinic acid 200mg/m2 iv infusion day 1, Oxaliplatin 85mg/m2 iv infusion day 1, Docetaxel 50mg/m2 iv day 1, Fluorouracil 2600mg/m2 over 24 hours iv) and the PD-L1 inhibiting monoclonal antibody Avelumab. The safe dose of Avelumab in combination with FLOT will be established in a safety run-in phase with a standard 3+3 design, starting with the recommended dose of 10mg/kg iv Avelumab (dose level 0) in which a dose reduction to 7mg/kg iv (dose level -1) may occur. Four cycles of two-weekly chemo-immunotherapy will be administered before surgery and four further cycles post-operatively in patients who are fit enough to receive further chemo-immunotherapy after surgery. Resectional surgery will take place 4-8 weeks following the last dose of chemo-immunotherapy in patients who remain fit.

Study Objectives:

To evaluate the safety, efficacy and toxicities and to explore biomarkers of peri-operative chemo-immunotherapy with Avelumab and FLOT.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

40 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

All patients will receive chemo-immunotherapy consisting of FLOT chemotherapy and the PD-L1 inhibiting monoclonal antibody Avelumab. Four cycles of two-weekly chemo-immunotherapy will be administered before surgery and four further cycles post-operatively in patients who are fit enough to receive further chemo-immunotherapy after surgery. Resectional surgery will take place 4-8 weeks following the last dose of chemo-immunotherapy in patients who remain fit.All patients will receive chemo-immunotherapy consisting of FLOT chemotherapy and the PD-L1 inhibiting monoclonal antibody Avelumab. Four cycles of two-weekly chemo-immunotherapy will be administered before surgery and four further cycles post-operatively in patients who are fit enough to receive further chemo-immunotherapy after surgery. Resectional surgery will take place 4-8 weeks following the last dose of chemo-immunotherapy in patients who remain fit.

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial)

Actual Study Start Date :

Jul 31, 2017

Anticipated Primary Completion Date :

Apr 15, 2021

Anticipated Study Completion Date :

Aug 15, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: FLOT plus Avelumab (FLOT-A) Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour. Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv	Drug: FLOT-A This is a single-arm study with all patients receiving combination FLOT-A

Arm

Intervention/Treatment

Experimental: FLOT plus Avelumab (FLOT-A)

Avelumab 10mg/kg (or Maximum Administered Dose established in safety run-in) iv infusion over 1 hour. Followed by FLOT: Oxaliplatin 85mg/m2 iv infusion day 1 over 2 hours, Folinic acid 200mg/m2 iv infusion day 1 over 2 hours, Docetaxel 50mg/m2 iv day 1 over 1 hour, Fluorouracil 2600mg/m2 over 24 hours iv

Drug: FLOT-A

This is a single-arm study with all patients receiving combination FLOT-A

Outcome Measures

Primary Outcome Measures

Pathological complete response rate of combination FLOT-A [Within 2 years of study opening]
The primary objective is to assess the efficacy of FLOT-A in the peri-operative setting in patients with operable GOAs. We aim to increase the pCR rate after peri-operative treatment from 10% (minimum expected path CR rate for peri-operative FLOT chemotherapy), to a superior pCR rate of >25%, by adding Avelumab to FLOT. Complete histopathologic response is defined by no vital tumour cells neither in the oesophagus, the stomach nor in the regional lymph nodes. In cases of residual tumour, the response assessment will follow criteria described by Mandard et al.

Secondary Outcome Measures

Number of participants with grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0 [Within 2 years]
Safety of peri-operative FLOT-A will be assessed by summarising grade 3-4 toxicity and DLT rates as proportions.
Radiological response rate using RECIST 1.1 criteria [Within 3 years]
Radiological response rate assessed at the pre-operative scan using RECIST 1.1 criteria. Radiological tumour response before surgery will be defined as partial response or complete response.
Median progression free survival by Kaplan Meir method [Within 5 years]
PFS will be summarised using Kaplan Meier methods, presenting median survival with 95% confidence intervals. PFS is defined as time from registration to clinical/radiological progression or death from any cause. Patients event free at time of analysis will be censored at last follow-up date.
Median overall survival by Kaplan Meir method [Within 5 years]
OS will be summarised using Kaplan Meier method, presenting median survival with 95% confidence intervals. OS is defined as time from registration to date of death of any cause. Patients event free at time of analysis will be censored at last follow-up date.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male/female patients aged ≥18 years
Histologically confirmed gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (referred to as gastro-oesophageal adenocarcinoma (GOA) in this protocol).
Oesophageal and gastric tumours should be TNM7 stage T1-3 and N0-N2, with no evidence of distant metastases (M0) where the MDT believes that an R0 resection can be achieved at the outset. T4 tumours will be excluded due to the variable need to prolong pre-operative chemotherapy or chemo-radiotherapy as part of locally advanced protocol to reduce margin involvement and improve resectability.
Absence of distant metastases on CT scan and PET scan and staging laparoscopy (where indicated) prior to study entry
No prior therapy for GOA
Considered fit for surgery by surgical/anaesthetic team
Adequate bone marrow function:

Absolute neutrophil count (ANC) >1.5x10-9/L
White blood count >3x10-9/L
Platelets ≥100x10-9/L
Haemoglobin (Hb) >9g/dL (can be post-transfusion)

Adequate renal function: Creatinine Clearance of >50ml/min or measured EDTA Clearance of ≥50ml/min. If the calculated Creatinine Clearance is <60ml/min then a measured EDTA Clearance is required. If available, the EDTA Clearance should always take precedence over the Creatinine Clearance.
Adequate liver function

Serum bilirubin <22 umol/L
ALT/AST ≤2.5x ULN

Adequate coagulation profile

International Normalised Ratio (INR) < 1.5
Activated Prothrombin Time (APTT) < 1.5xULN

Patients on oral anticoagulation are advised to change to low molecular weight heparin prior to study entry, to be eligible
ECOG performance status 0 or 1
Body Mass Index (BMI) ≤30
Patient is fit to undergo all protocol investigations and receive all protocol treatment based on the assessment in the surgical and oncology clinics. Signed and dated informed consent document indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrolment.
Willingness and ability to comply with the protocol for the duration of the study including scheduled visits, examinations, investigations and treatment plans

Exclusion Criteria:

Patients are not eligible for the trial if any of the exclusion criteria below are met:

Any contraindication or known hypersensitivity reaction to any of the study drugs, or components of Folinic acid, Oxaliplatin, 5FU or Docetaxel
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI CTCAE v 4.0), any history of anaphylaxis, or uncontrolled asthma (i.e., 3 or more features of partially controlled asthma)
Known dihydropyrimidine dehydrogenase (DPD) deficiency
Patients who have received chemotherapy, radiotherapy or immunotherapy for a previous malignancy
Any previous malignancy, with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer
Patients recommended to have radiotherapy as part of routine management for their GOA are ineligible
Any immunodeficiency disorder
Any active, known or suspected autoimmune disease that might deteriorate when receiving immunostimulatory agent, with the following exceptions:

Patients with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
Patients requiring hormone replacement with corticosteroids are eligible if the steroids are administered only for the purpose of hormonal replacement and at doses ≤10mg (or equivalent) of prednisolone per day
Administration of steroids through a route known to result in minimal systemic exposure (topical, intranasal intra-ocular, or inhalation) are acceptable

Prior organ transplantation, including allogeneic stem-cell transplantation
History of inflammatory bowel disease
Patients with a history of interstitial lung disease or radiological evidence of pulmonary fibrosis
Cerebrovascular disease (including transient ischaemic attacks (TIA) and strokes) within the previous year
Cardiovascular diseases as follows:

Myocardial infarction within the previous year
Serious cardiac arrhythmia requiring medication (for example, ventricular tachycardia, supraventricular tachycardia or atrial fibrillation with a resting heart rate > 110bpm)
Unstable angina
Congestive cardiac arrhythmia (New York Heart Association Classification Class II or above)

Current signs or symptoms of any other severe progressive or uncontrolled hepatic, haematologic, gastrointestinal, endocrine, respiratory or cardiac disease other than directly related to gastro-oesophageal adenocarcinoma, which in the opinion of the investigator, might impair the subject's tolerance of trial treatment or procedures.
Major surgery, major trauma or open biopsy within 28 days prior to registration (not including staging laparoscopy)
Evidence of bleeding diathesis or coagulopathy
Active non-healing wound, ulcer or bone fracture requiring therapy
Known positive tests for human immunodeficiency virus (HIV) infection, hepatitis A or C virus, acute or chronic active hepatitis B infection
Known peripheral neuropathy > grade 1 (absence of deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible)
Use of live attenuated vaccine within 28 days of initiation of study therapy, or anticipation that a live attenuated vaccine will be required during the study
Pregnancy/of child bearing potential. Pregnancy must be excluded with a negative serum pregnancy test, within 7 days before initiation of therapy, if the risk of conception exists. Sexually active female patients must be surgically sterile or be postmenopausal or must agree to use highly effective contraception. Sexually active male patients must be surgically sterile or must agree to use highly effective contraception, i.e. methods with a failure rate of <1% per year (see section 5.4 for full definition and examples of highly effective contraception).
Lactation- breast-feeding is contraindicated and must be discontinued for the duration of the trial and for up to 6 months afterwards.
Any patient specific factors which are likely to interfere with compliance of trial specific procedures or treatment.